Increased circulating soluble CD40 levels in patients with slow coronary flow phenomenon: An observational study;Koroner yavaş akım hastalarında kanda artmış CD40 konsantrasyonu: Bir gözlemsel çalışma

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 1, 2013, Pages 39-44

  Emre Durakoǧlugil, Murtaza ^a   Altan Kocaman, Sinan ^b   Çetin, Mustafa ^b   Kirbaş, Aynur ^a   Çanga, Aytun ^b   Erdoǧan, Turan ^a   Çiçek, Yüksel ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^b Rize Education and Research Hospital   (Turkey)

Author keywords

C reactive protein; Coronary angiography; Regression analysis; Slow coronary flow; Soluble CD40

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CROSS-SECTIONAL STUDY; FEMALE; FLOW RATE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL;

EID: 84874530030     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.005     Document Type: Article

References (38)

1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J 1972; 84: 66-71. [CrossRef]
2. Goel PK, Gupta SK, Agarwal A, Kapoor A. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology 2001; 52: 507-14. [CrossRef]
3. Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996; 37: 375-81. [CrossRef]
4. Cin VG, Pekdemir H, Camsar A, Çiçek D, Akkuş MN, Parmaksiz T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003; 44: 907-19. [CrossRef]
5. Sezgin AT, Siǧirci A, Barutçu I, Topal E, Sezgin N, Özdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14: 155-61. [CrossRef]
6. Riza Erbay A, Turhan H, Yaşar AS, Ayaz S, Şahin O, Senen K, et al. Elevated level of plasma homocysteine in patients with slow coronary flow. Int J Cardiol 2005; 102: 419-23. [CrossRef]
7. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986; 74: 964-72. [CrossRef]
8. Fragasso G, Chierchia SL, Arioli F, Carandente O, Gerosa S, Carlino M, et al. Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis. Int J Cardiol 2009; 137: 137-44. [CrossRef]
9. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80-2. [CrossRef]
10. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4. [CrossRef]
11. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43. [CrossRef]
12. Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007; 2: 256-68. [CrossRef]
13. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88. [CrossRef]
14. Kurtoǧlu N, Akcay A, Dindar I. Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol 2001; 87: 777-9, A8.
15. Pekdemir H, Polat G, Cin VG, Camsari A, Çicek D, Akkuş MN, et al. Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 2004; 97: 35-41. [CrossRef]
16. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, Heyndrickx GR, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but Normal coronary angiography. Circulation 2001; 104: 2401-6. [CrossRef]
17. Li JJ, Xu B, Li ZC, Qian J, Wei BQ. Is slow coronary flow associated with inflammation? Med Hypotheses 2006; 66: 504-8. [CrossRef]
18. Turhan H, Saydam GS, Erbay AR, Ayaz S, Yaşar AS, Aksoy Y, et al. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol 2006; 108: 224-30. [CrossRef]
19. Lanza GA, Andreotti F, Sestito A, Sciahbasi A, Crea F, Maseri A. Platelet aggregability in cardiac syndrome X. Eur Heart J 2001; 22: 1924-30. [CrossRef]
20. Gökçe M, Kaplan S, Tekelioǧlu Y, Erdoǧan T, Küçükosmanoǧlu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol 2005; 28: 145-8. [CrossRef]
21. Çamsari A, Pekdemir H, Çicek D, Polat G, Akkuş MN, Döven O, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003; 67: 1022-8. [CrossRef]
22. Yildiz A, Gür M, Yilmaz R, Demirbaǧ R, Polat M, Selek S, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008; 197: 257-63. [CrossRef]
23. Enli Y, Türk M, Akbay R, Evrengül H, Tanriverdi H, Kuru O, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther 2008; 25: 37-44. [CrossRef]
24. Kopetz V, Kennedy J, Heresztyn T, Stafford I, Willoughby SR, Beltrame JF. Endothelial function, oxidative stress and inflammatory studies in chronic coronary slow flow phenomenon patients. Cardiology 2012; 121: 197-203. [CrossRef]
25. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002; 12: 27-32. [CrossRef]
26. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995; 155: 4917-25.
27. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156: 3952-60.
28. Zhou L, Stordeur P, de Lavareille A, Thielemans K, Capel P, Goldman M, et al. CD40 engagement on endothelial cells promotes tissue factordependent procoagulant activity. Thromb Haemost 1998; 79: 1025-8.
29. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106: 981-6. [CrossRef]
30. Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A 2001; 98: 1751-6. [CrossRef]
31. Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem 2003; 278: 32801-9. [CrossRef]
32. De Paoli P, Cozzi M, Tedeschi R, Gloghini A, Cilia AM, van Kooten C, et al. High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants. Cytometry 1997; 30: 33-8. [CrossRef]
33. Mulhaupt F, Matter CM, Kwak BR, Pelli G, Veillard NR, Burger F, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59: 755-66. [CrossRef]
34. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation, 2002; 106: 2888-93. [CrossRef]
35. Ari H, Ari S, Erdoǧan E, Tiryakioǧlu O, Huysal K, Koca V, et al. The effects of endothelial dysfunction and inflammation on slow coronary flow. Turk Kardiyol Dern Ars 2010; 38: 327-33.
36. Yazici M, Aksakal E, Demircan S, Şahin M, Saǧkan O. Is slow coronary flow related with inflammation and procoagulant state? Anadolu Kardiyol Derg 2005; 5: 3-7.
37. Xia S, Deng SB, Wang Y, Xiao J, Du JL, Zhang Y, et al. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels 2011; 26: 480-6. [CrossRef]
38. Barutçu I, Sezgin AT, Sezgin N, Güllü H, Esen AM, Topal E, et al. Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology 2007; 58: 401-7. [CrossRef]